Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review

(2021) Alice Indini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy

(2021) Giuseppe Fanetti et al.   Nutrients

Biomarkers for immunotherapy response in head and neck cancer

(2020) Niki Gavrielatou et al.   CANCER TREATMENT REVIEWS

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

(2020) Lihong Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Determining Malnutrition Assessment Criteria to Predict One-Year Mortality for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy

(2020) Hang Huong Ling et al.   Nutrients

Obesity Paradox in Patients With Non–Small Cell Lung Cancer Treated With Immunotherapy

(2020) Alejandro Sanchez et al.   JAMA Oncology

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma

(2020) Arissa C Young et al.   Journal for ImmunoTherapy of Cancer

A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms

(2020) Heleen Konings et al.   Frontiers in Oncology

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

(2020) Alessio Cortellini et al.   Journal for ImmunoTherapy of Cancer

Clinical significance of pretreatment prognostic nutritional index and lymphocyte-to-monocyte ratio in patients with advanced p16-negative oropharyngeal cancer—a retrospective study

(2020) Ming-Hsien Tsai et al.   PeerJ

Clinical significance of prognostic nutritional index (PNI) in malignant melanoma

(2019) Cem Mirili et al.   International Journal of Clinical Oncology

Competition for nutrients and its role in controlling immune responses

(2019) Nidhi Kedia-Mehta et al.   Nature Communications

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients

(2019) Valentina Magri et al.   Cancer Management and Research

Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors

(2019) Fumihiro Shoji et al.   LUNG CANCER

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

(2019) Ganessan Kichenadasse et al.   JAMA Oncology

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

(2018) Jennifer L McQuade et al.   LANCET ONCOLOGY

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study

(2018) Georg Richtig et al.   PLoS One

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

(2018) Ziming Wang et al.   NATURE MEDICINE

The obese adipose tissue microenvironment in cancer development and progression

(2018) Daniela F. Quail et al.   Nature Reviews Endocrinology

Immunotherapy for Head and Neck Cancer

(2018) Felix Sim et al.   Oral and Maxillofacial Surgery Clinics of North America

The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy

(2017) Jingjing Miao et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Obesity Paradox in Cancer: a Review

(2016) Hannah Lennon et al.   Current Oncology Reports

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic Regulation of Immune Responses

(2014) Kirthana Ganeshan et al.   Annual Review of Immunology

Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis

(2014) Nadarajah Vigneswaran et al.   Oral and Maxillofacial Surgery Clinics of North America